Three CECT imaging features and one serum tumor marker were independently associated with HER2 status in GC: enhancement ratio in the arterial phase (odds ratio [OR] = 4.535; 95% confidence interval [CI], 2.220–9.264), intratumoral necrosis (OR = 2.64; 95% CI, 1.180–5.258), tumor margin (OR = 3.773; 95% CI, 1.968–7.235), and cancer antigen 125 (CA125) level (OR = 5.551; 95% CI, 1.361–22.651). This evidence concerns the gene ERBB2 and neoplasm.